Through use of a synthetic oligonucleotide probe, human insulin-like growth factor I (IGF-I) cDNA clones were isolated from a liver library. Two types of cDNAs were dermed by restriction enzyme analysis and DNA sequencing.
Both encode IGF-I precursors of either 195 or 153 amino acids. The two predicted protein precursors are identical from their amino terminus to a lysine residue 16 codons beyond the IGF-I sequence, and then they diverge. Both cDNAs predict additional unique carboxyl-terminal extension peptides. Since there is only one IGF-I gene in the human genome, the rmding of two different cDNAs suggests that alternative RNA processing plays a role in IGF-I gene expression. The functions of the different extension peptides remain to be elucidated.
The somatomedins or insulin-like growth factors (IGFs) comprise a family of peptides that circulate in plasma and stimulate DNA synthesis in a variety of cultured cells (1, 2) . Two human IGFs have been characterized. IGF-I, a 70-amino acid basic protein (3, 4) , plays a fundamental role in postnatal mammalian growth as the major mediator through which growth hormone (GH) exerts its biological effects (5, 6) . The function of IGF-II, a 67-amino acid neutral peptide (7, 8) , is less clear, as IGF-II serum levels do not show GH dependence (5, 9) , and unlike IGF-I, IGF-II cannot substitute for GH as a growth-promoting peptide (10) . Both IGFs circulate in blood bound to specific carrier proteins (11) .
Very little is known about IGF-I biosynthesis, in part because its content in tissues is low (12) , and also because, in contrast to IGF-II (8, 10) , no cultured cell lines elaborate significant quantities of the peptide (13, 14) . VassilopoulouSellin and Phillips (12) have estimated, by molecular sieve chromatography, that IGF-I activity extracted from rat liver has a higher molecular weight (=30,000) than activity extracted from plasma (Mr, =8000) and have asserted that the larger molecular weight material represents an IGF-I precursor. Amino acid sequence derived from a human IGF-I cDNA clone by Jansen et al. (15) supports the observation of a larger precursor, but since this cDNA is not full length the precise beginning of translation of IGF-I messenger RNA could not be determined.
Here I describe the characterization of two different IGF-I cDNAs isolated from a human liver library. The nucleotide sequences of these cDNAs predict two different IGF-I protein precursors and define the size of these peptides, 153 and 195 amino acids. The two IGF-I mRNAs have identical 5' ends and are expressed in human liver. Since current evidence points to the existence of only one IGF-I gene in the human genome (16) (17) (18) , these observations suggest that alternative RNA processing accounts for at least two different IGF-I mRNA species. As in other genes elaborating multiple peptides, tissue-specific regulation of RNA biosynthesis and maturation may play a role in IGF-I gene expression (19) (20) (21) (22) (23) (27) ] Following hybridization, the filters were washed for 15 min at 22°C and for 15 min at 40°C in 0.2x SSC/0.1% NaDodSO4, and exposed to Kodak XAR5 film with intensifying screens. Positive plaques were rescreened at lower density and purified to homogeneity. DNA was prepared (28) and mapped by restriction enzyme digestion and gel electrophoresis.
DNA sequence analysis. DNA sequencing was performed by the dideoxy-chain-terminating method (29, 30) after subcloning restriction fragments into M13 mpl8 and mpl9 bacteriophage (31) . The sequences of two cDNA isolates were determined in their entirety. DNA sequence was determined on both strands and across all restriction enzyme sites used as initiation points except for the extreme 3' end of one clone, which was sequenced three times in only one orientation. Data analysis was simplified by computer programs run on an Apple II microcomputer (32) and on a Digital Equipment Corporation VAX minicomputer. Protein homology searches were conducted by using the National BiomedAbbreviation: IGF, insulin-like growth factor.
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ical Research Foundation Protein Sequence Data Bank with the computer programs of Lipman and Pearson (33) . Nucleotide alignments were achieved by using the NUCALN program (34) .
RNA isolation and analysis. Liver polyadenylylated RNA was isolated from tissue fresh-frozen at -70'C by extraction with guanidinium thiocyanate (35) and one round of chromatography on oligo(dT) cellulose (36) . The polyadenylylated RNA was denatured with glyoxal (37), electrophoresed through a 1.25% agarose gel, and transferred to a nitrocellulose filter by blotting (38) . IGF-I cDNA probes were labeled with 32P by nick-translation (39) (40) . By comparison with the genomic sequence (unpublished data), the poly(A) tail is added commencing at position 1099.
The 585-nucleotide open reading frame begins with the second in-phase ATG codon. The first ATG at nucleotides 84-86 is followed immediately by an in-frame opal terminator. The open reading frame shown in Fig. 2 encodes a putative IGF-I precursor of 195 amino acids with a molecular weight of 21, 841 , assuming that the ATG codon at bases 183-185 initiates protein synthesis. At present, no direct evidence exists concerning the position of translation initiation. The mature IGF-I protein sequence is encoded by nucleotides 327-536 and is cross-hatched in Fig. 1 and underlined in Fig. 2 . The 70 IGF-I codons are followed by a predicted carboxyl-terminal extension of 77 amino acids and a stop codon.
Comparison of Two IGF-I cDNA Sequences Reveals Two IGF-I Protein Precursors. In Fig. 3 
DISCUSSION
In this report, I describe the characterization of two different cDNAs encoding human IGF-I, isolated from a liver cDNA library with an oligonucleotide probe. The DNA sequence reported defines an mRNA of 1136 nucleotides and represents a second type of IGF-I mRNA, IGF-IB, identical in its amino-terminal and IGF-I coding regions to a previously described cDNA (15) 15; unpublished results) . Second, the unique 3' region of IGF-IB cDNA hybridizes to human liver mRNA species of similar size to those hybridizing to IGF-IA cDNA, demonstrating that both messages are expressed in liver RNA. Third, and most compelling, in the human IGF-I gene the exons encoding the 3' ends of IGF-IA and IGF-IB mRNA lie on a single contiguous strand of DNA (unpublished results). Each IGF-I mRNA is thus encoded by the same gene. The existence of at least two IGF-I mRNA species in the face of current evidence for only one human IGF-I gene (17, 18) supports a model encompassing alternative RNA processing leading to the formation of IGF-I mRNA. Such alternative processing is not unprecedented and has been described for several genes (19, 20, 22, 23) . In one example, the calcitonin/calcitonin gene-related peptide (CGRP) gene, as yet unknown tissue-specific signals govern the exclusive expression of calcitonin in the medullary cells of the thyroid and CGRP in several areas of the central nervous system (41) can be found in the same tissue at a given time. Similarly, the two IGF-I mRNAs are concurrently expressed in liver, since both cDNA types hybridize to human liver RNA and since both were isolated from the Xgtll liver library. Discovery of the steps involved in IGF-I mRNA expression in different tissues awaits further study. The availability of distinct probes derived from the 3' end of each type of cDNA should facilitate such an analysis and make feasible experiments designed to look at tissue-specific IGF-I mRNA processing and regulation by specific hormonal mediators such as growth hormone (13, 14, 42, 43 consequence of tissue-specific regulation of IGF-I biogenesis. In addition, this observation raises the possibility that the amino and carboxyl peptides may have biological functions and that IGF-I, like pro-opiomelanocortin, may be a polyprotein (45) in which the biosynthesis of each component peptide is regulated in a tissue-specific way. Finally, the availability of the two IGF-I cDNA probes will facilitate characterization of the entire human IGF-I gene.
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